Inspire Medical Systems, Inc. INSP
We take great care to ensure that the data presented and summarized in this overview for Inspire Medical Systems, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INSP
View all-
Vanguard Group Inc Valley Forge, PA2.89MShares$403 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA1.95MShares$272 Million0.08% of portfolio
-
Black Rock Inc. New York, NY1.89MShares$264 Million0.01% of portfolio
-
Baillie Gifford & CO1.47MShares$205 Million0.25% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.1MShares$154 Million1.25% of portfolio
-
William Blair Investment Management, LLC Chicago, IL757KShares$105 Million0.44% of portfolio
-
Frontier Capital Management CO LLC685KShares$95.5 Million1.44% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT642KShares$89.5 Million0.81% of portfolio
-
Farallon Capital Management LLC San Francisco, CA627KShares$87.4 Million0.63% of portfolio
-
Jpmorgan Chase & CO New York, NY618KShares$86.2 Million0.01% of portfolio
Latest Institutional Activity in INSP
Top Purchases
Top Sells
About INSP
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Insider Transactions at INSP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 31
2024
|
Timothy P. Herbert CEO, President & Chairperson |
SELL
Bona fide gift
|
Indirect |
3,000
-2.59%
|
-
|
|
May 29
2024
|
Charisse Y Sparks Chief Medical Officer |
SELL
Bona fide gift
|
Direct |
64
-1.73%
|
-
|
|
May 10
2024
|
Shawn Mc Cormick Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+13.96%
|
$0
$0.94 P/Share
|
|
May 02
2024
|
Cynthia Burks Director |
BUY
Grant, award, or other acquisition
|
Direct |
716
+34.08%
|
-
|
|
May 02
2024
|
Gary Lee Ellis Director |
BUY
Grant, award, or other acquisition
|
Direct |
716
+15.12%
|
-
|
|
May 02
2024
|
Casey M Tansey Director |
BUY
Grant, award, or other acquisition
|
Direct |
716
+3.41%
|
-
|
|
May 02
2024
|
Dana G Mead Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
716
+3.24%
|
-
|
|
May 02
2024
|
Georgia Melenikiotou Director |
BUY
Grant, award, or other acquisition
|
Direct |
716
+25.41%
|
-
|
|
May 02
2024
|
Myriam Curet Director |
BUY
Grant, award, or other acquisition
|
Direct |
716
+25.43%
|
-
|
|
May 02
2024
|
Shawn Mc Cormick Director |
BUY
Grant, award, or other acquisition
|
Direct |
716
+5.26%
|
-
|
|
May 02
2024
|
Shelley G. Broader Director |
BUY
Grant, award, or other acquisition
|
Direct |
716
+23.69%
|
-
|
|
Apr 29
2024
|
Marilyn C Nelson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,175
+3.19%
|
$282,000
$240.68 P/Share
|
|
Apr 17
2024
|
Richard Buchholz Chief Financial Officer |
BUY
Bona fide gift
|
Indirect |
500
+8.47%
|
-
|
|
Apr 17
2024
|
Richard Buchholz Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
500
-1.77%
|
-
|
|
Apr 17
2024
|
Richard Buchholz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-34.67%
|
$3,450,000
$230.03 P/Share
|
|
Apr 12
2024
|
Shelley G. Broader Director |
BUY
Grant, award, or other acquisition
|
Direct |
70
+4.22%
|
$16,170
$231.74 P/Share
|
|
Apr 12
2024
|
Casey M Tansey Director |
BUY
Grant, award, or other acquisition
|
Direct |
62
+0.32%
|
$14,322
$231.74 P/Share
|
|
Apr 12
2024
|
Gary Lee Ellis Director |
BUY
Grant, award, or other acquisition
|
Direct |
70
+2.07%
|
$16,170
$231.74 P/Share
|
|
Apr 12
2024
|
Marilyn C Nelson Director |
BUY
Grant, award, or other acquisition
|
Direct |
107
+0.31%
|
$24,717
$231.74 P/Share
|
|
Apr 12
2024
|
Georgia Melenikiotou Director |
BUY
Grant, award, or other acquisition
|
Direct |
56
+3.88%
|
$12,936
$231.74 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 36.2K shares |
|---|---|
| Bona fide gift | 1.5K shares |
| Exercise of conversion of derivative security | 296K shares |
| Open market or private purchase | 100 shares |
| Bona fide gift | 55.8K shares |
|---|---|
| Open market or private sale | 138K shares |
| Payment of exercise price or tax liability | 98.9K shares |